<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-129287" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>COVID (SARS-CoV-2) Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-129287.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Multiple COVID-19 vaccines have received emergency use authorizations (EUA) to prevent severe COVID-19 illness caused by the SARS-CoV-2 virus. They have been instrumental in controlling the severity of this pandemic and improving clinical outcomes. Moreover, a novel approach to vaccination was initiated during this pandemic using mRNA vaccines. This activity reviews the indications, administration, and contraindications for COVID-19 vaccines to allow clinical understanding of these agents and their appropriate use. This activity will also highlight the mechanism of action, adverse event profile, and other key elements of the COVID-19 vaccines in the clinical setting for the interprofessional team members when vaccinating individuals to prevent COVID-19 and its related conditions sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of COVID-19 vaccines.</p></list-item><list-item><p>Describe indications for COVID-19 vaccines.</p></list-item><list-item><p>Review the adverse effects of the currently authorized COVID-19 vaccines.</p></list-item><list-item><p>Outline some interprofessional strategies the healthcare team can employ to optimize SARS-COVID-19 vaccine deployment and improve public health outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129287">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-129287.s2" sec-type="Indications">
        <title>Indications</title>
        <p>COVID-19 (coronavirus 2019) vaccines are indicated for the prevention of&#x000a0;coronavirus 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.<xref ref-type="bibr" rid="article-129287.r1">[1]</xref><xref ref-type="bibr" rid="article-129287.r2">[2]</xref><xref ref-type="bibr" rid="article-129287.r3">[3]</xref>&#x000a0;The SARS-CoV-2 virus first surfaced in Wuhan, China, in December 2019. The virus was announced as a public health emergency of International Concern on January 30, 2020, by the World Health Organization (WHO).<xref ref-type="bibr" rid="article-129287.r4">[4]</xref>&#x000a0;Since then, the lethal virus has spread rapidly, affecting various countries worldwide. On March 11, 2020,&#x000a0; the global COVID-19 occurrence was declared a pandemic by the WHO.<xref ref-type="bibr" rid="article-129287.r5">[5]</xref><xref ref-type="bibr" rid="article-129287.r6">[6]</xref></p>
        <p>The virus's transmission mode is mainly through infected individuals' respiratory droplets.<xref ref-type="bibr" rid="article-129287.r4">[4]</xref>&#x000a0;SARS-CoV-2 invades its host cells by binding&#x000a0;its viral spike (S) protein - constituted of S1 and S2 spike glycoprotein subunits and located on&#x000a0;its surface, to the human angiotensin-converting enzyme 2 (ACE2) receptors expressed on the surface epithelium of various organs and transmembrane protease, serine 2 (TMPRSS2) receptors.<xref ref-type="bibr" rid="article-129287.r7">[7]</xref><xref ref-type="bibr" rid="article-129287.r8">[8]</xref><xref ref-type="bibr" rid="article-129287.r9">[9]</xref></p>
        <p>The COVID-19 disease can have various manifestations, with increased susceptibility in individuals with comorbidities and immunosuppression.<xref ref-type="bibr" rid="article-129287.r10">[10]</xref><xref ref-type="bibr" rid="article-129287.r4">[4]</xref>&#x000a0;Individuals with underlying comorbid ailments are reported to have increased ACE2 expression.<xref ref-type="bibr" rid="article-129287.r11">[11]</xref>&#x000a0;Although the SARS-CoV-2 virus is predominantly a respiratory illness, extrapulmonary manifestations have been reported. The&#x000a0;symptoms&#x000a0;may present in two to fourteen days (with a mean of approximately five days) after exposure.<xref ref-type="bibr" rid="article-129287.r6">[6]</xref><xref ref-type="bibr" rid="article-129287.r10">[10]</xref>&#x000a0;The individual may be asymptomatic or exhibit mild to severe disease affecting multiple organs. Patients with mild to moderate disease usually present with fever, headache, chills, dry cough, shortness of breath, sore throat, nasal congestion, malaise, myalgia, body aches, nausea, and vomiting.</p>
        <p>Organ system manifestations include:</p>
        <p>
<bold>Respiratory</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild to severe pneumonia<xref ref-type="bibr" rid="article-129287.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Acute respiratory distress syndrome (ARDS)<xref ref-type="bibr" rid="article-129287.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Central Nervous System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Encephalopathy</p>
          </list-item>
          <list-item>
            <p>Cerebrovascular event</p>
          </list-item>
          <list-item>
            <p>Chemosensory dysfunction (altered taste and smell)<xref ref-type="bibr" rid="article-129287.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cardiovascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myocarditis</p>
          </list-item>
          <list-item>
            <p>Dysrhythmias<xref ref-type="bibr" rid="article-129287.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Coronary heart disease</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy<xref ref-type="bibr" rid="article-129287.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Renal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute kidney injury<xref ref-type="bibr" rid="article-129287.r15">[15]</xref><xref ref-type="bibr" rid="article-129287.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Moderate to severe diarrhea<xref ref-type="bibr" rid="article-129287.r17">[17]</xref><xref ref-type="bibr" rid="article-129287.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Currently Available Vaccines&#x000a0;</bold>
</p>
        <p>On December 11, 2020, an emergency use authorization (EUA) was granted by the US Food and Drug Administration (FDA) to the BNT162b2 vaccine to prevent COVID-19 illness with vaccine distribution in the US 48 hours later. Soon after, the second vaccine, mRNA-1273 SARS-CoV-2, was granted emergency use authorization on December 18, 2020.<xref ref-type="bibr" rid="article-129287.r19">[19]</xref><xref ref-type="bibr" rid="article-129287.r20">[20]</xref>&#x000a0;Both mRNA vaccines are designated for active immunization to prevent COVID-19 caused by SARS-CoV-2.<xref ref-type="bibr" rid="article-129287.r1">[1]</xref>&#x000a0;The third COVID-19 vaccine to receive EUA in the United States was&#x000a0;the Ad26.COV2.S on February 27, 2021.&#x000a0;The EUA was later revised and limited its use to people 18 years and above who are unable to access the approved COVID-19 vaccines or those choosing to receive the Ad26.COV2.S&#x000a0;vaccination. The fourth vaccination to receive EUA was the NVX-CoV2373 vaccine on July 13, 2022.</p>
        <p>On&#x000a0;August 23, 2021, the FDA approved its first COVID-19 vaccine, the&#x000a0;BNT162b2 - COVID-19 Vaccine, mRNA for individuals 12 years and above. The second approval was given on January 31, 2022, to the&#x000a0;mRNA-1273&#x000a0;- COVID-19 Vaccine, mRNA in individuals 18 years and above.</p>
        <p>
<bold>FDA Approved</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>BNT162b2 - for 12 years of age and above</p>
          </list-item>
          <list-item>
            <p>mRNA-1273-&#x000a0;for 18 years of age and above</p>
          </list-item>
        </list>
        <p>
<bold>FDA Emergency Use Authorization (EUA)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>BNT162b2&#x000a0;</bold>
<list list-type="bullet"><list-item><p>For individuals aged 6 months&#x000a0;to 4 years, the vaccine has EUA as a three-dose primary series.</p></list-item><list-item><p>For individuals aged&#x000a0;5 years and above, the vaccine has EUA as a two-dose primary series.</p></list-item><list-item><p>For immunocompromised individuals aged 5 years and older, the vaccine has EUA as a three-dose primary series.</p></list-item><list-item><p>A bivalent vaccine formulation to include the original vaccine and Omicron BA.4/BA.5 is now authorized as a booster dose for individuals aged 12 years or older.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>mRNA-1273&#x000a0;</bold>
<list list-type="bullet"><list-item><p>For individuals aged 12 to 17 years, the vaccine has EUA as a two-dose primary series.</p></list-item><list-item><p>For immunocompromised individuals aged 12 years and older, the vaccine has EUA as a three-dose primary series.</p></list-item><list-item><p>For individuals aged 6 months and above, the vaccine has EUA as a two-dose primary series.</p></list-item><list-item><p>For immunocompromised individuals aged 6 months and above, the vaccine has EUA for a third primary series dose.</p></list-item><list-item><p>A bivalent formulation of this vaccine with Omicron BA.4/BA.5 is authorized as a booster dose for individuals aged 18 years or older.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Ad26.COV2.S</bold>
<list list-type="bullet"><list-item><p>Single-dose primary vaccine in individuals aged 18 years and above.</p></list-item><list-item><p>Single dose booster&#x000a0;in individuals aged 18 years and above&#x000a0;two months following&#x000a0;the primary vaccination.</p></list-item><list-item><p>The EUA for this vaccine limits its use to individuals who cannot or elect not to use an mRNA vaccine due to the risk of vaccine-induced thrombotic thrombocytopenia.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>NVX-CoV2373</bold>
<list list-type="bullet"><list-item><p>It is an adjuvanted recombinant protein vaccine.</p></list-item><list-item><p>Authorized for individuals aged 12 years or older as a two-dose primary series.</p></list-item><list-item><p>Not authorized to be given as primary series for individuals with immunocompromising conditions.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Vaccine Efficacy</bold>
</p>
        <p>Covid-19 vaccines have been instrumental in curbing the intensity of this pandemic and decreasing the morbidity and mortality of this disease. COVID-19-associated hospitalizations and emergency/urgent care evaluations significantly improved with these vaccines.<xref ref-type="bibr" rid="article-129287.r21">[21]</xref>&#x000a0;A study from Israel stated that two doses of BNT162b2 were highly effective in preventing symptomatic and asymptomatic SARS-CoV-2 infections, as well as COVID-19-related hospitalizations, severe disease, and death.<xref ref-type="bibr" rid="article-129287.r22">[22]</xref></p>
        <p>A study from the United States evaluated the efficacy of&#x000a0;BNT162b2 and&#x000a0;mRNA-1273 vaccines in preventing severe illness for individuals at the highest risk of severe COVID-19 illness (those with advanced age and underlying comorbidities) by comparing their outcomes to unvaccinated individuals. The study stated that vaccine effectiveness 7 or more days after the second dose of the vaccine was 69% in preventing infection and 86% against severe disease/death.<xref ref-type="bibr" rid="article-129287.r23">[23]</xref>&#x000a0;They concluded that in an elderly population with a high-comorbidity burden, the vaccine effectiveness was lower than previously projected; however, the efficacy against death was high.</p>
      </sec>
      <sec id="article-129287.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mRNA class of vaccines' rapid evolution and advancements are from&#x000a0;the mRNA&#x000a0;capabilities to imitate the antigen structure and expression comparable to those&#x000a0;occurring during the SARS-CoV-2 infection.<xref ref-type="bibr" rid="article-129287.r24">[24]</xref>&#x000a0;The mRNA class of the vaccine does not pose&#x000a0;a risk of infection or insertional mutagenesis.&#x000a0;The mRNA eludes the anti-vector immunity permitting repeated vaccinations. The mRNA's ability to produce an undesired immune response within the body can be reduced, and modifications can be arranged to improve the mRNA vaccines' determination.<xref ref-type="bibr" rid="article-129287.r25">[25]</xref></p>
        <p>
<bold>BNT162b2</bold>
</p>
        <p>BNT162b2 is a nucleoside-modified messenger RNA (mRNA) expressed in lipid nanoparticles (LNP), encoding the spike (S) protein for the SARS-CoV-2 virus - the main site for neutralizing antibodies.<xref ref-type="bibr" rid="article-129287.r26">[26]</xref><xref ref-type="bibr" rid="article-129287.r27">[27]</xref>&#x000a0;The lipid particles allow the transfer of the RNA into host cells, resulting in the SARS-CoV-2 S antigens' expression.<xref ref-type="bibr" rid="article-129287.r24">[24]</xref>&#x000a0;The immunogenicity and antibody response to SARS-CoV-2 S antigens further confers protection against COVID-19.&#x000a0;</p>
        <p>
<bold>mRNA-1273&#x000a0;</bold>
</p>
        <p>The mRNA-1273 vaccine&#x000a0;is comprised&#x000a0;of a lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (mRNA), encoding the perfusion stabilized spike (S) protein&#x000a0;of the SARS-CoV-2 virus and an S1-S2 cleavage site, which includes a transmembrane component. The S-2P antigen present on its surface allows entrance into the host cell.&#x000a0;This further transfers the RNA into host cells, resulting in the expression of the SARS-CoV-2 S antigens. The immunogenicity and antibody response to SARS-CoV-2 S antigens also confers protection against COVID-19.<xref ref-type="bibr" rid="article-129287.r27">[27]</xref><xref ref-type="bibr" rid="article-129287.r24">[24]</xref></p>
        <p>
<bold>Ad26.COV2.S</bold>
</p>
        <p>The Ad26.COV2.S exerts its effects by expressing the SARS-CoV-2 S protein to human cells creating an immune response to the SARS-CoV-2 antigen, conferring immunity without dispersal of the virus. Different from the mRNA vaccines (BNT162b2 and mRNA-1273), the Ad26.COV2.S is a recombinant viral vector vaccine.&#x000a0;The Ad26.COV2.S recombinant viral vector vaccine bears DNA which forms the S protein of the SARS-CoV-2 virus, once injected into host cells, provide considerable amounts of the S protein antigen. The immune response to the S protein confers immunity by T-cells and B-cell stimulating antibodies to the S protein, similar to SARS-CoV-2 infection.<xref ref-type="bibr" rid="article-129287.r28">[28]</xref></p>
        <p>
<bold>NVX-CoV2373</bold>
</p>
        <p>This vaccine contains&#x000a0;recombinant spike (rS) protein nanoparticles and Matrix-M adjuvant proteins.&#x000a0;The rS protein is produced using recombinant DNA technology. Intramuscular injection of the full-length rS&#x000a0;protein elicits an&#x000a0;immune response to the rS protein, which protects against COVID-19 illness.<xref ref-type="bibr" rid="article-129287.r29">[29]</xref></p>
      </sec>
      <sec id="article-129287.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>BNT162b2</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For adults and children aged 12 and older:&#x000a0;The vaccine is administered intramuscularly (IM) as a series of two doses (0.3 ml each) 3 to 8 weeks apart.</p>
          </list-item>
          <list-item>
            <p>For children aged 5 to 11:&#x000a0;The vaccine is administered intramuscularly as a series of two doses (0.1 ml each) 3 to 8 weeks apart.</p>
          </list-item>
          <list-item>
            <p>For children six months to four years of age: The first two doses are 3 mcg given 3 to 8 weeks apart. The third dose is usually a 3 mcg of the bivalent vaccine given 8 weeks after the second dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For immunocompromised patients: The third dose is given&#x000a0;at least 28 days after the second dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The vaccine is distributed as a frozen suspension in a multiple-dose vial containing a volume of 0.45 ml that does not contain a preservative. After dilution with 1.8 ml of 0.9% sodium chloride injection, each vial contains up to 6 dosages of 0.3 ml. Vial labels and cartoons may state that after dilution, a vial contains five doses of 0.3 ml. Each 0.3 ml dose contains 30 mcg of mRNA, expressed in lipid nanoparticles encoding the spike (S) protein for the SARS-CoV-2 virus.</p>
          </list-item>
        </list>
        <p>
<bold>mRNA-1273&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The vaccine is administered intramuscularly as a series of two doses (100 mcg each) 4 to 8 weeks apart.</p>
          </list-item>
          <list-item>
            <p>The vaccine is distributed in 0.20 mg/ml white to off-white suspension rendered in vials containing&#x000a0;ten doses of 0.5 ml. Each vial dosage carries 100 micrograms of mRNA.</p>
          </list-item>
          <list-item>
            <p>For immunocompromised patients: The third dose is given at least 28 days after the second dose.</p>
          </list-item>
          <list-item>
            <p>For children 6 to 11 years of age: 2 IM doses of 50 mcg each given 4 to 8 weeks apart.</p>
          </list-item>
          <list-item>
            <p>For children six months to five years of age: 2 IM doses of 25 mcg each given 4 to 8 weeks apart.</p>
          </list-item>
        </list>
        <p>
<bold>Ad26.COV2.S</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The vaccine is administered as a single dose of 0.5 mL and authorized for individuals aged 18 years or&#x000a0;older&#x000a0;who cannot receive or elect not to receive mRNA COVID-19 vaccines.</p>
          </list-item>
          <list-item>
            <p>An additional dose with an mRNA monovalent vaccine is recommended for immunocompromised individuals.</p>
          </list-item>
        </list>
        <p>
<bold>NVX-CoV2373</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended dose is 2 IM injections of 5 mcg spike protein/50 mcg adjuvant protein for individuals aged 18 years or older, to be given 3 to 8 weeks apart.</p>
          </list-item>
          <list-item>
            <p>This vaccine is not authorized for individuals with immunocompromising conditions.</p>
          </list-item>
        </list>
        <p>
<bold>Booster Dose</bold>
</p>
        <p>The United States Centers for Disease Control and Prevention (CDC) recommends booster doses for all individuals aged five years and older. The preferred vaccine for booster dosing is a bivalent mRNA COVID-19 vaccine, which contains the original SARS-CoV-2 strain (in the monovalent BNT16b2 and mRNA-1273 vaccines) and the SAR-CoV-2 Omicron BA.4 and BA.5 variant strains.<xref ref-type="bibr" rid="article-129287.r30">[30]</xref>&#x000a0;The bivalent booster should be given at least two months after the last COVID-19 vaccine dose.&#x000a0;Monovalent mRNA vaccines can no longer be used for booster doses.&#x000a0;</p>
        <p>For individuals 18 years or older who have completed a primary series and are unable or unwilling to receive an mRNA vaccine for a booster dose, a single dose of NVX-CoV2373 vaccine can be used if given at least six months after the COVID-19 vaccine.</p>
        <p>According to the CDC, COVID-19 vaccines may be coadministered with other vaccines.&#x000a0;</p>
      </sec>
      <sec id="article-129287.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>BNT162b2</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site tenderness/pain (84.1%)</p>
          </list-item>
          <list-item>
            <p>Injection site&#x000a0;swelling&#x000a0;(10.5%)</p>
          </list-item>
          <list-item>
            <p>Redness at the injection site (9.5%)</p>
          </list-item>
          <list-item>
            <p>Fever&#x000a0;(14.2%)</p>
          </list-item>
          <list-item>
            <p>Fatigue&#x000a0;(62.9%)</p>
          </list-item>
          <list-item>
            <p>Headache (55.1%)</p>
          </list-item>
          <list-item>
            <p>Muscle pain&#x000a0;(38.3%)</p>
          </list-item>
          <list-item>
            <p>Chills&#x000a0;(31.9%)</p>
          </list-item>
          <list-item>
            <p>Joint pain (23.6%)</p>
          </list-item>
          <list-item>
            <p>Nausea&#x000a0;(1.1%)</p>
          </list-item>
          <list-item>
            <p>Malaise (0.5%)</p>
          </list-item>
          <list-item>
            <p>Lymphadenopathy&#x000a0;(0.3%)</p>
          </list-item>
          <list-item>
            <p>Severe allergic reaction (rare)</p>
          </list-item>
          <list-item>
            <p>Temporary one-sided facial drooping (rare)<xref ref-type="bibr" rid="article-129287.r31">[31]</xref><xref ref-type="bibr" rid="article-129287.r3">[3]</xref><xref ref-type="bibr" rid="article-129287.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>During clinical trials, four serious adverse events related to the BNT162b2 vaccination were reported. Serious adverse events include lymphadenopathy - localized to the right axillary, paroxysmal ventricular arrhythmia, right lower limb paresthesia, and shoulder injury associated with vaccine injection.<xref ref-type="bibr" rid="article-129287.r3">[3]</xref>&#x000a0;Mortality was seen in two BNT162b2 vaccine recipients but was not considered associated with the vaccination, as per investigators. These deaths were&#x000a0;deemed to have been&#x000a0;from arteriosclerosis and cardiac arrest.&#x000a0;Mortality linked to Covid-19 following vaccine administration was not seen.</p>
        <p>
<bold>mRNA-1273</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site tenderness/pain (92.0%)</p>
          </list-item>
          <list-item>
            <p>Injection site&#x000a0;swelling&#x000a0;(14.7%)</p>
          </list-item>
          <list-item>
            <p>Injection site&#x000a0;redness&#x000a0;(10.0%)</p>
          </list-item>
          <list-item>
            <p>Fever (15.5%)</p>
          </list-item>
          <list-item>
            <p>Fatigue (70.0%)</p>
          </list-item>
          <list-item>
            <p>Headache&#x000a0;(64.7%)</p>
          </list-item>
          <list-item>
            <p>Muscle pain&#x000a0;(61.5%)</p>
          </list-item>
          <list-item>
            <p>Chills (45.4%)</p>
          </list-item>
          <list-item>
            <p>Joint pain&#x000a0;(46.4%)</p>
          </list-item>
          <list-item>
            <p>Swollen lymph nodes on injection site arm (1.1%)</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting&#x000a0;(23.0%)</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity (1.5%)<xref ref-type="bibr" rid="article-129287.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Serious adverse effects occurred in 1% of recipients of the&#x000a0;mRNA-1273 SARS-CoV-2 during the clinical trials. Three cases (&#x0003c;0.1%) of Bell's palsy were also reported during the clinical trials of&#x000a0;mRNA-1273 SARS-CoV-2.<xref ref-type="bibr" rid="article-129287.r2">[2]</xref></p>
        <p>
<bold>Ad26.COV2.S</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site tenderness/pain (33.3-62.4%)</p>
          </list-item>
          <list-item>
            <p>Injection site&#x000a0;swelling&#x000a0;(1.1-9.0%)</p>
          </list-item>
          <list-item>
            <p>Injection site&#x000a0;redness&#x000a0;(1.1-7.0%)</p>
          </list-item>
          <list-item>
            <p>headache (18.8-52.7%)</p>
          </list-item>
          <list-item>
            <p>fatigue (18.8-59.1%)</p>
          </list-item>
          <list-item>
            <p>myalgia (8.3-47.3%)</p>
          </list-item>
          <list-item>
            <p>fever (2.1-14.0%)</p>
          </list-item>
          <list-item>
            <p>nausea (12.3-14.0%)</p>
          </list-item>
        </list>
        <p>Adverse reactions varied based on age groups 18 to 59 years old and 60 to 65 and above. Serious adverse effects included&#x000a0;Thrombosis with Thrombocytopenia Syndrome (TTS),&#x000a0;Immune Thrombocytopenia (ITP),&#x000a0;Guillain-Barr&#x000e9; Syndrome (GBS), and syncope.</p>
        <p>
<bold>NVX-CoV2373</bold>
</p>
        <p>According to the FDA fact sheet,&#x000a0;solicited adverse reactions&#x000a0;following the administration of this vaccine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site pain/tenderness (82.2%)</p>
          </list-item>
          <list-item>
            <p>Fatigue/malaise (62.0%)</p>
          </list-item>
          <list-item>
            <p>Muscle pain (54.1%)</p>
          </list-item>
          <list-item>
            <p>Headache (52.9%)</p>
          </list-item>
          <list-item>
            <p>Joint pain (25.4%)</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting (15.6%)</p>
          </list-item>
          <list-item>
            <p>Injection site redness (7.0%)</p>
          </list-item>
          <list-item>
            <p>Fever (6.0%)</p>
          </list-item>
        </list>
        <p>Myocarditis, pericarditis, hypersensitivity reactions,&#x000a0;lymphadenopathy-related reactions, and decreased appetite were also reported in some patients following the administration of this vaccine.&#x000a0;</p>
      </sec>
      <sec id="article-129287.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>BNT162b2</bold>
</p>
        <p>The BNT162b2 vaccine is not recommended for individuals with a&#x000a0;known&#x000a0;history of severe allergic reactions to any vaccine's components.<xref ref-type="bibr" rid="article-129287.r33">[33]</xref>&#x000a0;The use of this vaccine in children under the age of&#x000a0;5 is not yet recommended. Pregnant or breastfeeding women must consult a doctor or pharmacist before receiving this vaccine.</p>
        <p>
<bold>mRNA-1273&#x000a0;</bold>
</p>
        <p>The mRNA-1273 SARS-CoV-2 vaccine is not recommended for individuals with a&#x000a0;known&#x000a0;history of severe allergic reactions to any vaccine's components. Data on its use in pregnancy has not been studied, and its associated risks are yet to be determined. Its uses in individuals under the age of 18 have not yet been analyzed.</p>
        <p>
<bold>Ad26.COV2.S</bold>
</p>
        <p>The Ad26.COV2.S vaccination is not recommended in individuals with a known history of hypersensitivity and anaphylactic-type reactions to any vaccine components, individuals with any vaccine components, and individuals with a history of thrombosis with thrombocytopenia after vaccination.</p>
        <p>
<bold>NVX-CoV2373</bold>
</p>
        <p>According to the FDA fact sheet, this vaccine should not be administered to&#x000a0;individuals with a known&#x000a0;history of severe allergic reactions to any vaccine component.&#x000a0;</p>
      </sec>
      <sec id="article-129287.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Immunocompromised vaccination recipients may not have a prominent immune response and should be routinely monitored.&#x000a0;Recipients of the vaccines should periodically monitor any new and unusual adverse effects and report them to their vaccination provider.</p>
        <p>Pregnant women planning to be vaccinated by the mRNA-1273 vaccine are encouraged to register in the pregnancy exposure registry. The registry monitors outcomes in pregnant women exposed to the mRNA-1273 vaccine.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The BNT162b2 vaccine postmarketing data showed elevated cardiac inflammatory risk (myocarditis and pericarditis) within seven days of completing the 2-dose series. Males aged 18-24 are most at risk, and males below 40 are at higher risk than females.</p>
          </list-item>
          <list-item>
            <p>The mRNA-1273 vaccine postmarketing data showed elevated cardiac inflammatory risk (myocarditis and pericarditis) within seven days of completing the 2-dose series. Males aged 12-17 are most at risk, and males below 40 are at higher risk than females.</p>
          </list-item>
          <list-item>
            <p>Thrombosis with Thrombocytopenia Syndrome (TTS),&#x000a0;Immune Thrombocytopenia (ITP), and Guillain-Barr&#x000e9; Syndrome (GBS) with the&#x000a0;Ad26.COV2.S vaccine has been reported.</p>
          </list-item>
          <list-item>
            <p>Syncope, altered immunocompetence, and limitations of vaccine effectiveness have also been reported in both mRNA vaccines (BNT162b2,mRNA-1273) and the&#x000a0;Ad26.COV2.S vaccine.</p>
          </list-item>
          <list-item>
            <p>Monitoring for allergic reactions and syncope has been advised by the FDA fact sheet following the administration of NVX-CoV2373 vaccines.</p>
          </list-item>
          <list-item>
            <p>Given the reports of myocarditis, pericarditis, hypersensitivity reactions, and lymphadenopathy-related reactions following&#x000a0;NVX-CoV2373 vaccines, appropriate workup and reporting to the CDC are advised when patients present with signs and symptoms consistent with these complications.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-129287.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>COVID-19 vaccines are intended to prevent the COVID-19 disease caused by the SARS-CoV- 2 virus. An interprofessional team consisting of clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists providing a holistic and integrated approach to preventing COVID-19 can help achieve the best possible outcomes for this disease. COVID-19 is a public health emergency that may manifest from mild symptoms to severe multi-system effects in all age groups. Vaccines are the key to limiting severe illness, even as new variants emerge.&#x000a0;</p>
        <p>Before receiving the vaccination, healthcare professionals providing the COVID-19 vaccination should thoroughly communicate and educate the vaccination recipients on the information presented in the "Fact Sheet for Recipients and Caregivers" before receiving these vaccinations. The healthcare provider should give a CDC vaccination card to each person receiving the vaccine with a return date to complete the two-dose series.</p>
        <p>The healthcare team should inform the recipients on the V-safe information sheet, a smartphone app that identifies possible adverse effects following the COVID-19 vaccination through texting, and a website survey. The provider should also register in the federal COVID-19 vaccination program and report any unusual or severe adverse effects to Vaccine Adverse Event Reporting System (VAERS). The vaccination information must be included in a proper state or local jurisdiction's preferred system, such as the Immunization Information System (IIS), by the healthcare professional providing the vaccine.</p>
        <p>The healthcare team should be prepared for&#x000a0;immediate allergic reactions and have the equipment and treatment, such as; epinephrine, antihistamines, stethoscopes, and blood pressure cuffs, on hand in case anaphylaxis occurs following vaccine administration. Providers should also be aware of the limited data on vaccines' interchangeability and complete the two-dose series with the same vaccination as the first dose. The healthcare team should also communicate the vaccination's effectiveness and advise that receiving a vaccine does not ensure protection for all recipients.</p>
        <p>Interprofessional communication is vital for establishing patient rapport and increasing public health measures to control the spread of the virus and disease within communities. Patients should be counseled on handwashing, wearing a mask,&#x000a0;maintaining a distance of 6 feet, and 14-day quarantine after suspected exposure to limit the spread of the virus. Individual, collective, and preventative measures can help stop the further spread of COVID-19. [Level 5]</p>
      </sec>
      <sec id="article-129287.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129287">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/129287/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=129287">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-129287.s10">
        <title>References</title>
        <ref id="article-129287.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joffe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jan</month>
            <day>19</day>
            <volume>325</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-222</page-range>
            <pub-id pub-id-type="pmid">33315069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baden</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>El Sahly</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Essink</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Diemert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rouphael</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>McGettigan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khetan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Segall</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brosz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fierro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Neuzil</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Janes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Follmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marovich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mascola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Polakowski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ledgerwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pajon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knightly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leav</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ivarsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zaks</surname>
                <given-names>T</given-names>
              </name>
              <collab>COVE Study Group</collab>
            </person-group>
            <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>04</day>
            <volume>384</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-416</page-range>
            <pub-id pub-id-type="pmid">33378609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polack</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kitchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Absalon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Marc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Zerbini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Roychoudhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koury</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalina</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Frenck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hammitt</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>T&#x000fc;reci</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Nell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000dc;nal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tresnan</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Mather</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dormitzer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <collab>C4591001 Clinical Trial Group</collab>
            </person-group>
            <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Dec</month>
            <day>31</day>
            <volume>383</volume>
            <issue>27</issue>
            <fpage>2603</fpage>
            <page-range>2603-2615</page-range>
            <pub-id pub-id-type="pmid">33301246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.</article-title>
            <source>Mil Med Res</source>
            <year>2020</year>
            <month>Mar</month>
            <day>13</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">32169119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cucinotta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vanelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>WHO Declares COVID-19 a Pandemic.</article-title>
            <source>Acta Biomed</source>
            <year>2020</year>
            <month>Mar</month>
            <day>19</day>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-160</page-range>
            <pub-id pub-id-type="pmid">32191675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dulebohn</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Di Napoli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Features, Evaluation, and Treatment of Coronavirus (COVID-19)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">32150360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Farzan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>61</volume>
            <issue>21</issue>
            <fpage>2738</fpage>
            <page-range>2738-43</page-range>
            <pub-id pub-id-type="pmid">15549175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>COVID-19 and the cardiovascular system.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2020</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>259</fpage>
            <page-range>259-260</page-range>
            <pub-id pub-id-type="pmid">32139904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>131</volume>
            <fpage>110678</fpage>
            <pub-id pub-id-type="pmid">32861070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanyaolu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okorie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marinkovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patidar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Younis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hosein</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Padda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mangat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Altaf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comorbidity and its Impact on Patients with COVID-19.</article-title>
            <source>SN Compr Clin Med</source>
            <year>2020</year>
            <volume>2</volume>
            <issue>8</issue>
            <fpage>1069</fpage>
            <page-range>1069-1076</page-range>
            <pub-id pub-id-type="pmid">32838147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CX</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shaipanich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Singhera</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Dorscheid</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19.</article-title>
            <source>Eur Respir J</source>
            <year>2020</year>
            <month>May</month>
            <volume>55</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32269089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Khehra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jaferi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The Neurological Complexities and Prognosis of COVID-19.</article-title>
            <source>SN Compr Clin Med</source>
            <year>2020</year>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>2025</fpage>
            <page-range>2025-2036</page-range>
            <pub-id pub-id-type="pmid">33015552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babapoor-Farrokhran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rasekhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Bozorgnia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amanullah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myocardial injury and COVID-19: Possible mechanisms.</article-title>
            <source>Life Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <day>15</day>
            <volume>253</volume>
            <fpage>117723</fpage>
            <pub-id pub-id-type="pmid">32360126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.</article-title>
            <source>Eur Heart J</source>
            <year>2020</year>
            <month>Jun</month>
            <day>07</day>
            <volume>41</volume>
            <issue>22</issue>
            <fpage>2070</fpage>
            <page-range>2070-2079</page-range>
            <pub-id pub-id-type="pmid">32391877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>1157</fpage>
            <page-range>1157-1165</page-range>
            <pub-id pub-id-type="pmid">32345702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estepa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jafar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Acute Renal Failure in Critically Ill COVID-19 Patients With a Focus on the Role of Renal Replacement Therapy: A Review of What We Know So Far.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jun</month>
            <day>03</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e8429</fpage>
            <pub-id pub-id-type="pmid">32642345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravindran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>To</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thuluvath</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal and Liver Manifestations of COVID-19.</article-title>
            <source>J Clin Exp Hepatol</source>
            <year>2020</year>
            <season>May-Jun</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-265</page-range>
            <pub-id pub-id-type="pmid">32405183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kopel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perisetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gajendran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boregowda</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical Insights into the Gastrointestinal Manifestations of COVID-19.</article-title>
            <source>Dig Dis Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>1932</fpage>
            <page-range>1932-1939</page-range>
            <pub-id pub-id-type="pmid">32447742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine.</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Dec</month>
            <day>11</day>
            <volume>371</volume>
            <fpage>m4799</fpage>
            <pub-id pub-id-type="pmid">33310748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Covid-19: Pfizer-BioNTech vaccine is rolled out in US.</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Dec</month>
            <day>14</day>
            <volume>371</volume>
            <fpage>m4836</fpage>
            <pub-id pub-id-type="pmid">33318040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stenehjem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grannis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Naleway</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>DeSilva</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bozio</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dascomb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Birch</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Irving</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kharbanda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goddard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grisel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fadel</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ferdinands</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fireman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arndorfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valvi</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zerbo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Demarco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Steffens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shifflett</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schrag</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Verani</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaglani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azziz-Baumgartner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>07</day>
            <volume>385</volume>
            <issue>15</issue>
            <fpage>1355</fpage>
            <page-range>1355-1371</page-range>
            <pub-id pub-id-type="pmid">34496194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Angulo</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Anis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smaja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mircus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Southern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jodar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Alroy-Preis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>15</day>
            <volume>397</volume>
            <issue>10287</issue>
            <fpage>1819</fpage>
            <page-range>1819-1829</page-range>
            <pub-id pub-id-type="pmid">33964222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannou</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>O'Hare</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bohnert</surname>
                <given-names>ASB</given-names>
              </name>
              <name>
                <surname>Boyko</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hynes</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>175</volume>
            <issue>3</issue>
            <fpage>352</fpage>
            <page-range>352-361</page-range>
            <pub-id pub-id-type="pmid">34928700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>COVID-19 Vaccine: A comprehensive status report.</article-title>
            <source>Virus Res</source>
            <year>2020</year>
            <month>Oct</month>
            <day>15</day>
            <volume>288</volume>
            <fpage>198114</fpage>
            <pub-id pub-id-type="pmid">32800805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mizuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.</article-title>
            <source>Vaccine</source>
            <year>2021</year>
            <month>Jan</month>
            <day>08</day>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-201</page-range>
            <pub-id pub-id-type="pmid">33279318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chien</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Zangi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>KO</given-names>
              </name>
            </person-group>
            <article-title>Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2014</year>
            <month>Oct</month>
            <day>09</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>a014035</fpage>
            <pub-id pub-id-type="pmid">25301935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heaton</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>The Covid-19 Vaccine-Development Multiverse.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>12</day>
            <volume>383</volume>
            <issue>20</issue>
            <fpage>1986</fpage>
            <page-range>1986-1988</page-range>
            <pub-id pub-id-type="pmid">32663910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mascellino</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Di Timoteo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety.</article-title>
            <source>Infect Drug Resist</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>3459</fpage>
            <page-range>3459-3476</page-range>
            <pub-id pub-id-type="pmid">34511939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Twentyman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roper</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Rubis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Moulia</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged &#x02265;18 years - United States, July 2022.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2022</year>
            <month>Aug</month>
            <day>05</day>
            <volume>71</volume>
            <issue>31</issue>
            <fpage>988</fpage>
            <page-range>988-992</page-range>
            <pub-id pub-id-type="pmid">35925807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zapata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ajmera</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaurasia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e29837</fpage>
            <pub-id pub-id-type="pmid">36204257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>A Nursing Researcher's Experience in a COVID-19 Vaccine Trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>01</day>
            <volume>181</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-158</page-range>
            <pub-id pub-id-type="pmid">33284328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabanillas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?</article-title>
            <source>Allergy</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>1617</fpage>
            <page-range>1617-1618</page-range>
            <pub-id pub-id-type="pmid">33320974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129287.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahase</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Covid-19: People with history of significant allergic reactions should not receive Pfizer vaccine, says regulator.</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Dec</month>
            <day>10</day>
            <volume>371</volume>
            <fpage>m4780</fpage>
            <pub-id pub-id-type="pmid">33303484</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
